**Summary of 4basebio PLC Half-Year Report (H1 2025)**
**Operational Highlights**
**Regulatory Milestone** Received MHRA GMP manufacturing license for the UK facility, enabling supply of Investigational Medicinal Product Drug Substance and Critical Starting Biological Materials.
**Intellectual Property Expansion** Increased patent portfolio to 31 families, strengthening leadership in synthetic DNA.
**Client Progress** A pharmaceutical partner secured FDA IND approval for an mRNA vaccine using 4basebio’s DNA, with other clients advancing programs toward clinical trials.
**Financial Highlights**
**Revenue Growth** £1.2 million in H1 2025, a 25% increase from full-year 2024, driven by accelerating adoption of synthetic DNA.
**Cash Position** £26.1 million in cash balances post-equity increase in 2024.
**Loss** £7.8 million (vs. £5.7 million in H1 2024) due to strategic investments in technology, manufacturing, and commercial capabilities.
**Net Cash Outflow** £8.2 million from operating activities (vs. £5.1 million in H1 2024).
**Strategic Focus**
Shifted mRNA focus toward gene editing and cancer immunotherapy due to softening in infectious disease mRNA vaccine market.
Expanding into viral-based cell and gene therapy programs, leveraging enzymatic DNA’s safety advantages.
Validating the Hermesâ„¢ platform for nucleic acid vaccine applications, showing strong commercial potential.
**Business Outlook**
Expects continued pipelineclient baseand revenue growth in H2 2025.
Ongoing investments in people, technology, and capabilities will exceed revenues, resulting in a full-year loss.
Well-capitalized to deliver on ambitions, supported by prior equity investment.
**Key Statements**
CEO Dr. Heikki Lanckriet highlighted revenue growth, regulatory approval, and the long-term potential of the synthetic DNA market.
Chairwoman Manja Boerman emphasized regulatory milestones, revenue validation, and strategic investments in commercial and GMP activities.
**Financial Position**
Non-current assets increased to £8.2 million, while current assets decreased to £28.7 million due to cash outflows.
Closing cash balances at £26.1 million, with long-term liabilities at £15.4 million.
Share capital increased slightly due to employee share incentive plans.
**Post-Period Events**
Issued additional shares under employee share incentive plans, increasing total issued share capital.
**Conclusion**
4basebio PLC demonstrated significant operational and financial progress in H1 2025, reinforced by regulatory approvals, revenue growth, and strategic investments. Despite short-term losses, the company remains well-positioned for long-term growth in the synthetic DNA market, supported by a strong financial base and expanding commercial opportunities.